PureTech Share News (PRTC)
PRTC Share
PRTC Share
PRTC Share
PRTC Share
PRTC
PRTC Share
PRTC Level 2
PRTC Live
PRTC Broker
PRTC Directors
PRTC Financial
PRTC
PRTC Short
PRTC
Last checked at -
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Posts positive data from a phase 1 trial of its idiopathic pulmonary fibrosis drug candidate LYT-100, or deupirfenidone.
Read more(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, September 19 after completing its quarterly review.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.
Read morePureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Pretax loss in the first half 2022 narrows to USD56.0 million from USD94.9 million a year before. This is due to a USD28.4 million gain on the dilution of its equity interest in Gelesis Inc. Revenue grows 21% to USD7.0 million from USD5.8 million. Attributes this to increased grant revenue from the Vedanta CARB-X and BARDA grant, as well as Alivio and PureTech LYT Inc.
Read more
(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.
Read morePureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says its founded entity, Sonde Health, has signed a multi-year agreement with specialty pharmaceutical company Koye Pharmaceuticals Pvt Ltd. The agreement is to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This is Sonde's first partnership with a pharmaceutical firm, PureTech adds.
Read more(Alliance News) - Almost 18 months after announcing a name change, abrdn PLC's blue-chip status is under threat, according to indicative index changes provided by FTSE Russell on Tuesday.
Read more(Alliance News) - PureTech Health PLC said founded entity Akili Inc will start trading on the Nasdaq Capital Market on Monday, after raising funds which will go towards video-game based treatment for children.
Read more(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc.
Read more(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.
Read morePureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.
Read morePureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read morePureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Begins late-stage clinical study of its wholly-owned candidate LYT-100, or deupirfenidone, in idiopathic pulmonary fibrosis. Will evaluate efficacy of two doses, as well as relative tolerability and efficacy with pirfenidone. IPF is a chronic condition causing progressive scarring of the lungs, which currently has a poor prognosis. Also advances LYT-200 programme through clinical development, and plans to begin leukemia study by the end of 2022.
Read more
Last checked at